Skip to main content
. 2021 May 28;11(6):802. doi: 10.3390/biom11060802

Figure 2.

Figure 2

Known SARS-CoV PLpro inhibitors used as candidates during covalent and non-covalent ligand docking against OTUB1/OTUB2 and SARS-CoV-2 PLpro. Studied covalent linkage sites for ‘nucleophilic addition to a double bond’ marked (*) and site which follows ‘Michael addition’ marked (**) in the compounds.